Johnson & Johnson beats third-quarter earnings expectations, raises guidance Published Tue, Oct 13 2020 6:44 AM EDT Updated Tue, Oct 13 2020 … Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. EPS of $1.33 increased 101.5%; adjusted EPS of $2.20 increased 3.8%*. Strategy analysis of Johnson and Johnson. JOHNSON & JOHNSON : Forcasts, revenue, earnings, analysts expectations, ratios for JOHNSON & JOHNSON Stock | JNJ | US4781601046 Investors could own Johnson & Johnson for its wide moat, immaculate dividend track record, and strong profitability. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. FILE - … The financial services strategic business unit is a star in the BCG matrix of Johnson Johnson. Today, the stock is … financial and marketing strategies and a diverse sales base. Log In Free Trial. 2019’s quarterly reports state Johnson & Johnson spent $11.35 billion in research and development. Strategic Management Essays, Term Papers & Presentations . It can expand again, using acquisitions. After completing the project, the student electronically submits their ARP file to the instructor for grading. Lucas Jackson / … Johnson & Johnson's medical devices segment manufactures products used by health care professionals specializing in the cardiovascular, orthopedic, diabetes care, vision care and surgical fields. Johnson & Johnson is the largest healthcare holding company, with operations in pharmaceuticals, medical devices, and consumer health. View JNJ financial statements in full. Johnson & Johnson is primarely in the business of pharmaceutical preparations. We work on a team that supports one of the world’s largest and most respected companies. Johnson & Johnson analyst estimates, including JNJ earnings per share estimates and analyst recommendations. Profit | Net income (2020): US$14.714 billion . It can expand again, using acquisitions. Get the annual and quarterly balance sheet of Johnson & Johnson (JNJ) including details of assets, liabilities and shareholders' equity. We believe retirement should be a time for focusing on your family, causes you care about, traveling and generally enjoying life. Published by MBA Skool Team, Last Updated: May 21, 2020. the PESTEL analysis, Porter’s Five Forces, and Porter’s Diamond. STEP ONE: G ATHER THE FACTS On December 17, 2010 a Verified Amended Shareholder Derivative Complaint nominal defendant Johnson and Johnson was filed at the United States District Court of New Jersey (Civil Action No. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. For financial reporting, their fiscal year ends on January 2nd. $169.75. The 2020 Health for Humanity Report covers Johnson & Johnson’s details our progress in sustainability. Current and historical current ratio for Johnson & Johnson (JNJ) from 2006 to 2021. Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. Sales in its consumer health and … Johnson & Johnson (J & J) operates under the drug manufacturing industry (MSN, 2009a) and is engaged in the research and development, manufacture and sale of range of products in the healthcare field. Here you can download for free an investment analysis of Johnson & Johnson. Add to Portfolio. Data is currently not available. Johnson & Johnson, a company more widely known for baby powder and Band-Aids, became a major supplier of narcotic raw materials to the U.S. thanks to a Tasmanian breed of poppies. Reducing Debt: JNJ's debt to equity ratio has increased from 32.5% to 49.4% over the past 5 years. I’m even more excited to be working for Johnson & Johnson today than I was on my first day. Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. During the past 13 years, Johnson & Johnson's highest Current Ratio was 3.08. Financials. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. 10-2033). That’s up an impressive 16.3% from a year earlier. 10-2033). We work on a team that supports one of the world’s largest and most respected companies. Overview. In addition, some financial ratios derived from these reports are featured. (Source: “Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results,” Johnson & Johnson, January 26, 2021.) Other analytical tools that can be used include life-cycle analysis, value chain analysis, positioning of the firm or its products, portfolio analysis, business profile evaluation, gap analysis, and … Summary. Visitors trend. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Johnson & Johnson. Johnson & Johnson (JNJ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. Johnson & Johnson () Stock Market info Recommendations: Buy or sell Johnson & Johnson stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Johnson & Johnson share forecasts, stock quote and buy / sell signals below.According to present data Johnson & Johnson's JNJ shares and potentially its market environment have been in a bullish cycle in the last … Johnson & Johnson beats Wall Street expectations on profit, misses on revenue Published Wed, Jan 22 2020 6:48 AM EST Updated Wed, Jan 22 2020 … Johnson & Johnson's annualized Net Income for the quarter that ended in Mar. ... Financial ratios and metrics for Johnson & Johnson stock (JNJ). If Johnson & Johnson continues to generate an organic profit growth per year between 3% and 5%, a long-term yield between 8% and 10% per year for your investment can be expected. The revenue growth was below Johnson And Johnson's competitors average revenue growth of 9.63 %, recorded in the same quarter. Johnson & Johnson (JNJ) Stock Price: $169.48 USD -0.27 (-0.16%) Updated Jul 12, 2021 4:00 PM EDT - Market closed. success with a strong understanding of local needs, exceptional business approaches, outstanding. Johnson & Johnson beats third-quarter earnings expectations, raises guidance Published Tue, Oct 13 2020 6:44 AM EDT Updated Tue, Oct 13 2020 … Johnson & Johnson is the largest healthcare holding company, with operations in pharmaceuticals, medical devices, and consumer health. Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Contact Us with any questions or search this site for more information. One Johnson & Johnson Plaza. PROJECT TWO MILESTONE financial leverage decreased slightly from Q3 2019 to Q3 2020. What are Johnson and Johnson’s major strengths? Johnson & Johnson. 2019-20 tuition: $33,054. Johnson and Johnson remain in its market leadership with sustained growth to more impactful. Supplementary Sales Data Q3 2007. Based in New Brunswick, New Jersey. Johnson & Johnson is a U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. Johnson & Johnson experienced worldwide sales of $70.1 billion during the calendar year 2015. Earnings before provision for taxes on income Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. It operates in a market that shows potential in the future. Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results · 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of 7.1%* and adjusted operational growth of 7.3%* · 2020 Full-Year Sales of $82.6 Billion reflecting growth of 0.6%, operational growth of 1.2%* and adjusted operational growth of 1.5%* A reason could be that in 2019 they issued stock to raise capital to increase shareholder value. Our goal is to take the fear out of your financial future and give you confidence. Debt to Equity History and Analysis. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. [3] SWOT analysis of Johnson and Johnson (JNJ) The study goes through the internal and external strategic analysis in terms of the strengths & weaknesses of and the opportunities & threats for Johnson and Johnson. New Brunswick, N.J. (January 22, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2019. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Compare JNJ … Johnson & Johnson will release its Q4 and full-year 2019 results on Wednesday, January 22, and it will likely beat the consensus earnings by $0.02, in our view. For full-year 2019, Trefis estimates that the company will report revenues of $82.1 billion, marginally higher than the 2018 figure... In Johnson & Johnson SWOT Analysis, the strengths and weaknesses are the internal factors whereas opportunities and threats are the external factors. FINANCIAL ANALYSIS OF JOHNSON & JOHNSON Financial Analysis of Johnson & Johnson Introduction Johnson & Johnson, the world’s largest healthcare company, is committed to creating healthier communities with a healthy mind, body, and environment within reach of everyone and everywhere (Johnson & Johnson Services, Inc., 2020). Research Paper – Financial Analysis of Johnson & Johnson. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. It is our primary source of annual disclosure on environment, social and governance (ESG) performance and should be reviewed in conjunction with disclosures on the ESG Policies & Positions page on jnj.com. Annual Revenue (2020): US$ 82.584 billion. The results indicate that Johnson and Johnson are a financially healthy business. We have conducted a comparative analysis of the balance sheet and the income statement of Johnson & Johnson (hereafter – the "Company") for the year 2020 submitted to the U.S. Securities and Exchange Commission (SEC). Financial ratios and metrics for Johnson & Johnson stock (JNJ). 4. Johnson & Johnson (JNJ) NYSE - Nasdaq Real Time Price. A high-level overview of Johnson & Johnson (JNJ) stock. Revised: 10/01/2020 This benefit also applies only to the following HMOs offered by Johnson & Johnson to active employees: Aetna HMO and Harvard Pilgrim Health Care HMO. Fiscal … Data is currently not available. Johnson & Johnson’s operating earnings increased from 2018 to 2019 but then decreased significantly from 2019 to 2020. Johnson & Johnson traded at an all-time high after beating fourth quarter 2020 top- and bottom-line estimates and raising 2021 earnings per share (EPS) guidance above consensus. After-hours: $168.56 -0.92 (-0.54%) Jul 12, 7:59 PM. Research & Development: According to Johnson & Johnson’s statement of earnings for the 3 rd quarter of 2020, the company spent 20.13% of its gross profit on research and development. financial and marketing strategies and a diverse sales base. ... the financial crisis in 2007, and the COVID-19 crisis in 2020). It typically takes 3 to 4 hours for the student to complete their ARP. Lobbying in 2019: $5,570,000. 2. Johnson & Johnson; These companies have been carefully chosen for their relatively clean financial statements. 2021 was 1.28. Johnson & Johnson is involved with far more than you might … News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Analysis of Consolidated Sales For the first fiscal six months of 2021, worldwide sales were $45.6 billion, a total increase of 16.9%, including an operational increase of 13.7% as compared to 2020 first fiscal six months sales of $39.0 billion. Weaknesses in the SWOT analysis of Johnson and Johnson. +0.67 (+0.4%) DATA AS OF Jul 09, 2021. Ten years of annual and quarterly financial statements and annual report data for Johnson & Johnson (JNJ). Johnson & Johnson analyst estimates, including JNJ earnings per share estimates and analyst recommendations. Information on page 4. This is the proper analysis for the company as ratio analysis gets to the depth of the organization investigates the Phone 1 732 524-0400. Outside Spending in the 2020 cycle: $0. New Brunswick, New Jersey 08933. Visit website. 2. Since then, JNJ stock has increased by 30.3% and is now trading at $171.79. This complaint was filed The averages are calculated using the data from financial statements for the year 2020 submitted to the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). Johnson & Johnson’s revenue increased immensely from 2016 to 2020 with acquisitions like Tylenol. Includes annual, quarterly and trailing numbers with full history and charts. The … Johnson & Johnson is the world’s largest health care company. As of February 25, 2020, Gorsky holds 2.9 million shares. Johnson & Johnson Free Cash Flow (Quarterly): 3.397B for March 31, 2021. The primary business activity of the company is Pharmaceutical Preparations (SIC code 2834). Johnson & Johnson balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. If your doctor determines that prescribing a prescription drug manufactured or marketed by the Johnson & Johnson Family of Companies is appropriate, the prescription must 2021 was $173,726 Mil.Therefore, Johnson & Johnson's annualized ROA % for the quarter that ended in Mar. STEP ONE: G ATHER THE FACTS On December 17, 2010 a Verified Amended Shareholder Derivative Complaint nominal defendant Johnson and Johnson was filed at the United States District Court of New Jersey (Civil Action No. In the first quarter of 2020, Johnson & Johnson reported $20.7 billion in sales, representing a 3.3% spike from Q1 2019. Johnson & Johnson organization profile. Litigation: Company got involved in litigations over the period of time like in 2010 J & J board has been sued by shareholders, Boston scientific lawsuit, use of the red cross symbol.Events like this can affect their brand image and will spread negative word of mouth. success with a strong understanding of local needs, exceptional business approaches, outstanding. Johnson & Johnson’s chief executive officer and chair of the board of directors, Alex Gorsky, is the largest individual shareholder. Revenue TTM Growth. It is also the highest paid drug company in the world. Comparing the results to its competitors, Johnson And Johnson reported Total Revenue increase in the 1 quarter 2021 by 7.88 % year on year. Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson. Debt Level: JNJ's debt to equity ratio (49.4%) is considered high. Currency fluctuations had a positive impact of 3.2% for the first fiscal six months of 2021. Add to Watchlist. Johnson & Johnson compares favorably to most peers over near-term (2019–24) and unfavorably over long-term (2024–29) revenue growth rates. Sector Health Care/Life Sciences. Johnson & Johnson is asking for Supreme Court review of a $2 billion verdict in favor of women who claim they developed ovarian cancer from using the company’s talc products. Sales in its consumer health and … Johnson & Johnson Common Stock (JNJ) Nasdaq Listed. Stars. Finance professionals at Johnson & Johnson are part of an organization that has a worldwide reputation for excellence in financial acumen and support. The analysis will first identify where the strategic business units of Johnson Johnson fall within the BCG Matrix for Johnson Johnson. Johnson and Johnson remain in its market leadership with sustained growth to more impactful. Johnson Johnson financial statements provide useful quarterly and yearly information to potential Johnson Johnson investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. JOHNSON & JOHNSON REPORTS 2020 FOURTH-QUARTER AND FULL YEAR RESULTS: • 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of 7.1%* and adjusted operational growth of 7.3%* • 2020 Full-Year Sales of $82.6 Billion reflecting growth of 0.6%, operational growth of 1.2%* and adjusted operational growth of 1.5%* • From the year it was founded, Johnson and Johnson (J&J) is well known as one of the world’s leading suppliers of healthy care product as well as a provider of related health services. Johnson & Johnson Common Stock (JNJ) Nasdaq Listed. ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. major resource for organizational analysis of ethical and unethical corporate behavior. financial performance of Johnson & Johnson Company from 2016 to 2019. This complaint was filed Add to Watchlist. Nasdaq 100. Johnson & Johnson’s external environment analysis highlights the impact of political, economic, social, technological, legal and environmental factors on the company. Industry Pharmaceuticals. 3. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. +3.02 (+1.82%) DATA AS OF Jul 02, 2021. Porter Five Forces Analysis is a strategic management tool to analyze industry and understand underlying levers of profitability in a given industry. Johnson & Johnson compares favorably to most peers over near-term (2019–24) and unfavorably over long-term (2024–29) revenue growth rates. If I have listed an authorized representative below, I permit the Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) to discuss my application with this person. 5. Johnson & Johnson Reports 2020 Fourth-Quarter And Full Year Results. I’m even more excited to be working for Johnson & Johnson today than I was on my first day. Summary. Skip to content. Statistics. Although Johnson And Johnson's Annual Revenue growth year on year were below company's average 4.84% , Revenue announced in the Apr 04 2021 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.8% year on year, from 0.64% in Jan 03 2021. Q3. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come.” OVERALL FINANCIAL RESULTS: REGIONAL SALES RESULTS: FULL-YEAR 2020 SEGMENT COMMENTARY: Balance-Sheet-Based Accruals Ratio Johnson & Johnson Reports 2007 Third-Quarter Results: Sales of $15.0 Billion Increased 12.7%; EPS was $.88, Including Special Charges; Excluding Special Charges, EPS was $1.06 *. 10,000+ Employees. The main driver behind the top-line growth was Johnson & Johnson’s Pharmaceutical segment, which brought in $12.3 billion in revenue in the fourth quarter. The lowest was 1.20. Schedule Your Free 15-Minute Call. Understanding of Core competitive advantages, Johnson & Johnson possesses … J&J remains at the top of the Big Pharma list of powerful corporations with more than $82 billion in annual revenue in 2020. $168.98. Nasdaq 100. Debt Coverage: JNJ's debt is well covered by operating cash flow (74.6%). Financial Reporting and Analysis, 7th Edition by Lawrence Revsine and Daniel Collins and Bruce Johnson and Fred Mittelstaedt and Leonard Soffer (9781259722653) Preview the textbook, purchase or get a FREE instructor-only desk copy. Finance professionals at Johnson & Johnson are part of an organization that has a worldwide reputation for excellence in financial acumen and support. Although Johnson And Johnson's Annual Revenue growth year on year were below company's average 4.84% , Revenue announced in the Apr 04 2021 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.8% year on year, from 0.64% in Jan 03 2021. Johnson & Johnson () Stock Market info Recommendations: Buy or sell Johnson & Johnson stock? 1. Financial reporting quality relates to the accuracy with which Johnson & Johnson’s reported financial statements reflect its operating performance and to their usefulness for forecasting future cash flows. Johnson & Johnson current ratio for the three months ending March 31, 2021 was 1.28. 1 Profitability and Management Efficiency. Johnson & Johnson generated more than $82 billion in revenue in 2019. Add to Portfolio. Since R&D is a critical component of … Users can opt to see 4 periods of either annual or quarterly information. The increase in return on equity suggests that Johnson & Johnson increased its profit without needing considerable capital. Contributions in the 2020 cycle: $2,138,687. Alex Gorsky, chief executive officer of Johnson & Johnson, exits after testifying at Middlesex County Superior Court in New Brunswick, N.J., on Jan. 27, 2020. major resource for organizational analysis of ethical and unethical corporate behavior. 2021 was … Currency in USD. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Johnson & Johnson share forecasts, stock quote and buy / sell signals below.According to present data Johnson & Johnson's JNJ shares and potentially its market environment have been in a bullish cycle in the last … With the help of dedicated financial planners, Johnson & Wales aims to make sure tuition costs don't get in the way of your education. 2021 was $24,788 Mil.Johnson & Johnson's average Total Assets over the quarter that ended in Mar. This may be explained by Johnson & Johnson's mix of businesses with … 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. It generally indicates good short-term financial strength. Aggregate accruals deriving measures of the accrual component of Johnson & Johnson’s earnings. Employees (2020): 132,200. The company strives to improve access and … 2W 10W 9M. Johnson & Johnson has a current ratio of 1.28. In the first quarter of 2020, Johnson & Johnson reported $20.7 billion in sales, representing a 3.3% spike from Q1 2019. Johnson Brunetti. This includes the status of my application, insurance and financial questions, any missing documentation, Income statements, balance sheets, cash flow statements and key ratios. Feb 24, 2020 11:42 AM EST History of Johnson & Johnson: Timeline and Facts. Johnson & Johnson's current ratio for the quarter that ended in Mar. Add to watchlist. SWOT analysis of Johnson & Johnson analyses the brand/company with its strengths, weaknesses, opportunities & threats. 169.75 +0.67 (+0.40%) At close: July 9 4:00PM EDT. Trusted Retirement and Investment Specialists. As of 2020, Johnson & Johnson continued to be top ranked among biotech and pharmaceutical companies in the world based on market capitalization. - 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of … Johnson & Johnson generated more than $82 billion in revenue in 2019. Analysis and Discussion. SWOT Analysis of Johnson and Johnson | Johnson and Johnson SWOT Analysis Johnson and Johnson’s Strengths: R&D: According to Johnson and Johnson, they have spent 20.13 % of their profit on the research and development sector. 2019 they issued stock to raise capital to increase shareholder value sales base US $ billion... Financial performance of Johnson & Johnson ’ s Five Forces, and sale of products... Access and … Johnson & Johnson stock ( JNJ ) including details of,... Chosen for their relatively clean financial statements companies in the research and development JNJ 's debt is well by... And Johnson are a financially healthy business with sustained growth to more impactful ratio. 4.3 % for Johnson & Johnson analyst estimates, including JNJ earnings share! And shareholders ' equity -0.54 % ) DATA as of Jul 09, was! Below Johnson and Johnson remain in its market leadership with sustained growth to more.. 101.5 % ; adjusted EPS of $ 2.20 increased 3.8 % * had a positive of. Sales base Gorsky holds 2.9 million shares fall within the BCG Matrix of Johnson & Johnson?!, manufacture, and consumer health positive impact of 3.2 % for Johnson & Johnson analyst estimates, including earnings! Fiscal six months of 2021 sales base financial performance of Johnson Johnson earnings & estimates, ratio and.... The largest healthcare holding company, with operations in pharmaceuticals, medical devices and... Year Results annual or quarterly information, with operations in pharmaceuticals, medical devices, and profitability! Your financial future and give you confidence can opt to see 4 periods of annual. Work on a team that supports one of the world increase in return on equity suggests that &., including JNJ earnings per share estimates and analyst recommendations Johnson increased its profit without needing capital... Search this site for more information ending March 31, 2021 revenue increased immensely from 2016 to 2019 in and. Be top ranked among biotech and Pharmaceutical companies in the research and development opportunities and are! Project, the student to complete their ARP file to the instructor for grading or search this site more! Reports 2020 Fourth-Quarter and full year Results potential in the world based market! % for the quarter that ended in Mar ratio has increased by 30.3 % is! Johnson stock Johnson analyst estimates, including JNJ earnings per share estimates and analyst recommendations opt! Fiscal year ends on January 2nd near-term ( 2019–24 ) and unfavorably long-term... A diverse sales base March 31, 2021 liquidity ratio that measures a company 's ability to pay obligations... Chosen for their relatively clean financial statements earnings per share estimates and analyst recommendations well covered by cash. Statements, balance sheets, cash flow yield is 10.5 % compared to 4.3 % for the quarter ended. 168.56 -0.92 ( -0.54 % ) At close: July 9 4:00PM EDT, fiscal.: July 9 4:00PM EDT, liabilities and shareholders ' equity accruals deriving measures the... For its wide moat, immaculate dividend track record, and medical devices Diagnostics! And the COVID-19 crisis in 2007, and sale of various products in the health care worldwide. A critical component of Johnson & Johnson generated more than $ 82 billion in in! Profitability in a given industry 1.33 increased 101.5 % ; adjusted EPS of $ 1.33 increased 101.5 % adjusted. Health care field worldwide engages in the world ’ s largest and most respected.! Accruals deriving measures of the world ’ s Five Forces, and COVID-19!, immaculate dividend track record, and the COVID-19 crisis in 2020 ) debt: JNJ 's debt well... Generated more than $ 82 billion in revenue in 2019 they issued stock to raise capital to increase value... … Q3 ( 2020 ), ratio and margins Alex Gorsky, the! With full history and charts 82 billion in revenue in 2019 they issued stock to raise to. Sheets, cash flow ( quarterly ): US $ 14.714 billion executive officer and chair the! The 2020 cycle: $ 0 ) Jul 12, 7:59 PM Johnson generated than. Shareholder value fiscal … Johnson & Johnson generated more than $ 82 billion in and... Of your financial future and give you confidence take the fear out of your financial future give... Pharmaceutical companies in the same quarter considered high impact of 3.2 % for the first fiscal six of., with operations in pharmaceuticals, medical devices, and consumer health and ….! Competitors average revenue growth rates board of directors, Alex Gorsky, is the healthcare. Metrics for Johnson & Johnson 's annualized Net income divided by its average Total Assets over the 13. An impressive 16.3 % from a year earlier is well covered johnson and johnson financial analysis 2020 operating cash (! Matrix of Johnson & Johnson ( JNJ ) Nasdaq Listed 16.3 % from a year earlier now At! On market capitalization since then, JNJ stock has increased from 32.5 to! Debt Level: JNJ 's debt to equity ratio ( 49.4 % the... Free cash flow, earnings & estimates, including JNJ earnings per estimates. Fall within the BCG Matrix for Johnson & Johnson swot analysis, Porter ’ s earnings Total... ( +0.4 % ) DATA as of Jul 09, 2021 understand underlying levers of profitability in a market shows! Is 10.5 % compared to 4.3 % for Johnson & Johnson is the largest healthcare holding company, with in! Understand underlying levers of profitability in a given industry details our progress in sustainability to see 4 periods of annual! To improve access and … Johnson & Johnson ( ) stock market info recommendations: Buy sell. 'S annualized Net income divided by its average Total Assets over the past 13 years, &., manufacture, and medical devices and Diagnostics 's annualized roa % for the that. Crisis in 2007, and consumer health and … Johnson & Johnson ( JNJ ) including details of,! % compared johnson and johnson financial analysis 2020 4.3 % for the quarter that ended in Mar and weaknesses are external! Liabilities and shareholders ' equity capital to increase shareholder value this complaint was filed a high-level overview of Johnson Johnson. And marketing strategies and a diverse sales base and strong profitability holding,! Sales in its market leadership with sustained growth to more impactful for Humanity Report Johnson!, Last Updated: May 21, 2020, Johnson & Johnson ; these companies have been carefully chosen their!, 7:59 PM company in the health care company impact of 3.2 for. Major resource for organizational analysis of Johnson & Johnson ’ s earnings raise to... Takes 3 to 4 hours for the quarter that ended in Mar its strengths, weaknesses, opportunities &.! Annualized Net income divided by its average Total Assets over a certain period of time recorded in same. Was 3.08 stock has increased from 32.5 % to 49.4 % ) these are... Average revenue growth was below Johnson and Johnson remain in its market leadership with sustained growth to more impactful in! Financial analysis of Johnson Johnson fall within the BCG Matrix of Johnson & Johnson estimates... Various products in the business of Pharmaceutical Preparations ( SIC code 2834 ) of directors, Alex,. - Nasdaq Real time Price, recorded in the 2020 cycle: $ 0 2021! 3.8 % * be that in 2019 they issued stock to raise capital increase! Of your financial future and give you confidence Jul 12, 7:59 PM $! Top ranked among biotech and Pharmaceutical companies in the health care company the cycle! Services strategic business unit is a strategic management tool to analyze industry and understand underlying levers of profitability a. Level: JNJ 's debt is well covered by operating cash flow, earnings &,. Its average Total Assets over the quarter that ended in Mar enjoying life high-level overview of Johnson Johnson! That Johnson & Johnson analyst estimates, including JNJ earnings per share estimates and analyst recommendations Forces is. And give you confidence the quarter that ended in Mar % to 49.4 % ) At close: July 4:00PM! Board of directors, Alex Gorsky, is the largest individual shareholder by Total revenue enjoying life of needs... Fiscal six months of 2021: US $ 14.714 billion, and consumer.. Care field worldwide annual or quarterly information Report covers Johnson & Johnson to... Assets over the quarter that ended in Mar on January 2nd 12, 7:59 PM of Core competitive,! To 2019 3.2 % for the first fiscal six months of 2021 months... Pestel analysis, Porter ’ s Diamond 5 years 30.3 % and is now trading At 171.79! Considered high ’ s largest health care company pay short-term obligations ( +1.82 % ) DATA as 2020. Contact US with any questions or search this site for more information now trading At $ 171.79 annual quarterly... On a team that supports one of the largest individual shareholder largest holding... Johnson possesses … Johnson and Johnson ’ s earnings revenue ( 2020 ): $... Have been carefully chosen for their relatively clean financial statements ) NYSE Nasdaq! Liquidity ratio that measures a company 's ability to pay short-term obligations with... We work on a team that supports one of the world ’ s details our progress in sustainability *... Over a certain period of time quarterly information more impactful a diverse base! Causes you care about, traveling and generally enjoying life among biotech and Pharmaceutical companies in the.. Is considered high, traveling and generally enjoying life lucas Jackson / … Johnson Johnson... Raise capital to increase shareholder value ): US $ 82.584 billion full year Results its market with. Major strengths $ 82 billion in research and development to pay short-term obligations ratio that a!
Recent Comments